3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
57
Neoplasms
11
Lung Neoplasms
11
Small Cell Lung Carcinoma
8
Thyroid Neoplasms
7
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Carcinoma
6
Breast Neoplasms
6
Adenocarcinoma
6
Colorectal Neoplasms
5
Colonic Neoplasms
5
Thyroid Diseases
4
Thyroid Cancer, Papillary
4
Thoracic Neoplasms
4
Sarcoma
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Pancreatic Neoplasms
4
Neuroendocrine Tumors
4
Neoplasms by Site
4
Melanoma
4
Lung Diseases
4
Endometrial Neoplasms
4
Endocrine System Diseases
4
Endocrine Gland Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Bronchogenic
4
Bronchial Neoplasms
4
Uterine Cervical Neoplasms
3
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Non Small Cell Lung Cancer NSCLC
×
Thoracic
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA